Sonoma Pharmaceuticals

SNOA

Market cap $5.46M

SNOA Hedge Fund Activity: Q1 2026 in Review

17 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2026, worth a combined $144K — down 64% from $396K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SNOA positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $11.8K. The largest seller was DRW Securities, cutting an estimated $143K.

• 17 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2026, up from 16 in Q4 2025.
• Funds reported $144K of Sonoma Pharmaceuticals stock for Q1 2026, down 64% quarter-over-quarter.
• 4 funds opened new Sonoma Pharmaceuticals positions in Q1 2026 and 1 closed out, a net change of +3 holders.
• The largest Sonoma Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $11.8K added.
• The largest Sonoma Pharmaceuticals seller in Q1 2026 was DRW Securities, an estimated $143K sold.

Based on aggregated 13F filings for Q1 2026.